EPT Disclosure

RNS Number:5350D
Deutsche Bank AG London
24 May 2006


                                                            FORM 38.5(a)

                 DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS

                      WITH RECOGNISED INTERMEDIARY STATUS

                      DEALING IN A CLIENT-SERVING CAPACITY

                      (Rule 38.5(a) of the Takeover Code)



1.         KEY INFORMATION


Name of exempt principal trader                Deutsche Bank AG London
Company dealt in                               Cambridge Antibody Technology Group Plc
Class of relevant security to which the        Ordinary
dealings being disclosed relate (Note 1)

Date of dealing                                23/05/2006






2.         DEALINGS (Note 2)



(a)        Purchases and sales


Total number of securities purchased   Highest price paid (Note 3)           Lowest price paid (Note 3)


160,852                                #13.08                                #13.00




Total number of securities sold        Highest price received (Note 3)       Lowest price received (Note 3)


9,788                                  #13.055                               #13.0365



(b)        Derivatives transactions (other than options)


Product name,         Long/short (Note 4)       Number of securities (Note 5)        Price per unit (Note 3)

e.g. CFD
CFD                   Long                      4,000                                #13.028907
CFD                   Long                      127,200                              #13.067162





(c)        Options transactions in respect of existing securities

(i)         Writing, selling, purchasing or varying


Product name,         Writing, selling, Number of securities  Exercise   Type, e.g.      Expiry     Option money
                        purchasing,     to which the option              American,
e.g. call option      varying etc.      relates (Note 5)      price      European etc.   date       paid/received per
                                                                                                    unit (Note 3)





(ii)        Exercising


Product name, e.g. call option         Number of securities                  Exercise price per unit (Note 3)
















3.         OTHER INFORMATION



Agreements, arrangements or understandings relating to options or derivatives




Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating
to the voting rights of any relevant securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is
referenced.  If none, this should be stated.











Date of disclosure                                                24/05/2006

Contact name                                                      Kelly-Jade Ledwich

Telephone number                                                  020 7545 7804

Name of offeree/offeror with which connected                      AstraZeneca Plc
Nature of connection (Note 6)                                     Adviser to the offeror






Notes



The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at
www.thetakeoverpanel.org.uk






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

EMMSEDFMLSMSEEI